Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 9.

Ghadjar, P; Simcock, M; Studer, G; Allal, A; Ozsahin, M; Bernier, J; Töpfer, M; Zimmermann, F; Betz, M; Glanzmann, C; Aebersold, D (2012). Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). International Journal of Radiation Oncology, Biology and Physics, 82(2):524-531.

von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mihic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23(2):531-536.

Schraml, P; von Teichman, A; Mihic-Probst, D; Simcock, M; Ochsenbein, A; Dummer, R; Michieilin, O; Seifert, B; Schläppi, M; Moch, H; von Moos, R (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 28(2):654-658.

Ghadjar, P; Simcock, M; Zimmermann, F; Betz, M; Bodis, S; Bernier, J; Studer, G; Aebersold, M (2012). Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiotherapy and Oncology, 104(2):213-218.

Hitz, F; Martinelli, G; Zucca, E; von Moos, R; Mingrone, W; Simcock, M; Peterson, J; Cogliatti, S B; Bertoni, F; Zimmermann, D R; Ghielmini, M (2009). A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological Oncology, 27(3):154-159.

Ghadjar, P; Blank-Liss, W; Simcock, M; Hegyi, I; Beer, K T; Moch, H; Aebersold, D M; Zimmer, Y (2009). MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clinical and Experimental Metastasis, 26(7):809-815.

Fux, C; Rauch, A; Simcock, M; Bucher, H; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss HIV Cohort Study (2008). Tenofovir Use Is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 13:1077-1082.

Sendi, P; Günthard, H F; Simcock, M; Ledergerber, B; Schüpbach, J; Battegay, M (2007). Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE, 2(1):e173.

Simcock, M; Sendi, P; Ledergerber, B; Keller, T; Schüpbach, J; Battegay, M; Günthard, H F (2006). A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? Antiviral Therapy, 11(3):305-314.

This list was generated on Fri Nov 24 15:46:38 2017 CET.